Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 224

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

Open access
Gay, Cynthia L., Bosch, Ronald J, Ritz, Justin, Hataye, Jason M., Aga, Evgenia, Tressler, Randall L., Mason, Stephen W., Hwang, Carey K., Grasela, Dennis M., Ray, Neelanjana, Cyktor, Josh C., Coffin, John M., Acosta, Edward P., Koup, Richard A., Mellors, John W., Eron, Joseph J., for the AIDS Clinical Trials 5326 Study Team · 2017 · The Journal of Infectious Diseases

Abstract

Background: Reversing immune exhaustion with an anti-PD-L1 antibody may improve human immunodeficiency virus type 1 (HIV-1)-specific immunity and increase clearance of HIV-1-expressing cells. Methods: We conducted a phase I, randomized, double-blind, placebo-controlled, dose-escalating study of BMS-936559, including HIV-1-infected adults aged >18 to <70 years on suppressive antiretroviral therapy with CD4+ counts >350 cells/μL and detectable plasma HIV-1 RNA by single-copy assay. Data on single infusions of BMS-936559 (0.3 mg/kg) versus placebo are described. The primary outcomes were safety defined as any grade 3 or greater or immune-related adverse event (AE) and the change in HIV-1 Gag-specific CD8+ T cell responses from baseline to day 28 after infusion. Results: Eight men enrolled: 6 received 0.3 mg/kg of BMS-936559, and 2 received placebo infusions. There were no BMS-936559-related grade 3 or greater AEs. In 1 participant, asymptomatic hypophysitis (a protocol-defined immune-related AE) was identified 266 days after BMS-936559 infusion; it resolved over time. The mean percentage of HIV-1 Gag-specific CD8+ T cells expressing interferon γ increased from baseline (0.09%) through day 28 (0.20%; P = .14), driven by substantial increases in 2 participants who received BMS-936559. Conclusions: In this first evaluation of an immunologic checkpoint inhibitor in healthy HIV-1-infected persons, single low-dose BMS-936559 infusions appeared to enhance HIV-1-specific immunity in a subset of participants. Clinical Trials Registration: NCT02028403.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jix191

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 224

Metadata

Authors
Gay, C. L., Bosch, R. J., Ritz, J., Hataye, J. M., Aga, E., Tressler, R. L., Mason, S. W., Hwang, C. K., Grasela, D. M., Ray, N., Cyktor, J. C., Coffin, J. M., Acosta, E. P., Koup, R. A., Mellors, J. W., Eron, J. J., & for the AIDS Clinical Trials 5326 Study Team
Venue
The Journal of Infectious Diseases
Published
2017-04-18
Volume
215
Issue
11
Pages
1725-1733
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2605530771
Cited by
224
References
7
FWCI
17.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. https://app.cochat.ai/papers/10.1093/infdis/jix191
The paper
Gay, C. L., Bosch, R. J., Ritz, J., Hataye, J. M., Aga, E., Tressler, R. L., Mason, S. W., Hwang, C. K., Grasela, D. M., Ray, N., Cyktor, J. C., Coffin, J. M., Acosta, E. P., Koup, R. A., Mellors, J. W., Eron, J. J., & for the AIDS Clinical Trials 5326 Study Team. (2017). Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jix191

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.